Nashat Gabrail - Concepedia

Author

Nashat Gabrail

Also Known As

Ann Silk, David A. Eberhard, Gabrail N, Marc Uemura, N Gabrail, N Y Gabrail, N. Gabrail, N. Y. Gabrail, N.Y. Gabrail, Nashat Gabrail

272

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

Gabrail Cancer Center The University of Texas MD Anderson Cancer Center Moffitt Cancer Center Princess Margaret Cancer Centre Cornell University

About

Nashat Gabrail is an author at Gabrail Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	36	3K
2	Health Sciences	6	6	944
3	Engineering	2	2	359
4	Anesthesia	1	1	155
5	Biomedical Engineering	1	1	58

Nashat Gabrail

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer Steven J. Cohen, Cornelis J.A. Punt, Nicholas Iannotti, Journal of Clinical Oncology	2008	1.8K
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial Adrian S. Dobs, Ralph V. Boccia, C. Croot, The Lancet Oncology MedicineCancer ManagementExercise PhysiologyBreast CancerMuscle Wasting	2013	376
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification Brendan Bulik‐Sullivan, Jennifer Busby, Christine D. Palmer, Nature Biotechnology Systems BiologyEngineeringDeep LearningMedicineMass Spectrometry	2018	301
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Ravi Vij, Michael Wang, Jonathan L. Kaufman, Blood	2012	254
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail, Journal of Clinical Oncology	2016	244
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Journal of Clinical Oncology	2013	227
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies David A. Rizzieri, Eric J. Feldman, John F. DiPersio, Clinical Cancer Research	2008	225
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer Charu Aggarwal, Neal J. Meropol, Cornelis J.A. Punt, Annals of Oncology Overall SurvivalGastrointestinal OncologyMedicinePathologyColorectal Cancer	2012	177

Page 1